文献速递妇科产科

晚期与复发性上皮性卵巢癌减瘤术联合腹腔热灌注化疗后的复发模式

Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
PubMed 文献 · Gynecol Oncol · 2021-02-05

单中心队列研究纳入92例晚期或复发性上皮性卵巢癌患者,接受减瘤术联合腹腔热灌注化疗。首次复发中约一半位于腹膜外,复发性手术组腹膜外复发与更优的无进展生存和总生存相关。

要点

  • 减瘤术联合腹腔热灌注化疗后约半数首次复发位于腹膜外
  • 间隔减瘤术组中腹膜外单独复发占40.0%
  • 复发性减瘤术组腹膜外复发者无进展生存与总生存更优

核心结论

  • 接受减瘤术联合腹腔热灌注化疗的晚期或复发性上皮性卵巢癌患者中,约半数首次复发位于腹膜外。

研究设计与样本

  • 单中心IRB批准的队列研究,纳入2014年12月1日至2020年3月1日前瞻性登记中接受减瘤术联合腹腔热灌注化疗的92例晚期或复发性上皮性卵巢癌患者。

主要发现

  • 间隔减瘤术联合腹腔热灌注化疗组复发部位为盆腔50.0%(n=15)、上腹部23.3%(n=7)、腹膜外56.7%(n=17),其中腹膜外单独复发占40.0%(n=12)。
  • 复发性减瘤术联合腹腔热灌注化疗组复发部位为盆腔22.5%(n=9)、上腹部5.0%(n=2)、腹膜外60.0%(n=24),其中腹膜外单独复发占66.7%(n=20)。
  • 两组合并分析,盆腔和上腹部复发对比腹膜外单独复发的中位无进展生存为10.5个月 vs 13.0个月(p=0.02),中位总生存为29.2个月 vs 未达到(p=0.05)。
  • 间隔减瘤术组中,盆腔和上腹部复发对比腹膜外单独复发的中位无进展生存(10.6 vs 11.7个月,p=0.68)和总生存(27.1 vs 24.8个月,p=0.96)无差异。
  • 复发性减瘤术组中,盆腔和上腹部复发对比腹膜外单独复发的无进展生存(10.0 vs 18.1个月,p=0.03)和总生存(33.6个月 vs 未达到,p=0.02)更差。

临床怎么用

  • 对接受减瘤术联合腹腔热灌注化疗的上皮性卵巢癌患者,应警惕腹膜外复发风险并进行相应随访监测。

局限性

  • 本研究为单中心队列研究,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): To identify recurrence patterns and outcomes in women with advanced or recurrent epithelial ovarian cancer (EOC) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: This is an IRB-approved single-institution cohort study of women who underwent CRS+HIPEC for advanced or recurrent EOC followed in a prospective registry from 1/12/2014-3/1/2020. Recurrence locations were defined as pelvic, upper abdominal (UA) and/or extra-peritoneal (EP). Univariate analysis assessed associations between recurrence location, progression-free survival (PFS), and overall survival (OS). RESULTS: In total, 92 women with EOC underwent interval (56.5%; n=52) or recurrent CRS+HIPEC (43.5%; n=40). For interval CRS+HIPEC, recurrence locations were pelvic in 50.0% (n=15), UA in 23.3% (n=7) and EP in 56.7% (n=17); 40.0% (n=12) were EP alone. Similarly, for recurrent CRS+HIPEC, recurrence locations were pelvic (22.5%, n=9), UA (5.0%, n=2) and EP (60.0%, n=24); 66.7% (n=20) were EP alone. For both interval and recurrent CRS+HIPEC, median PFS was 10.5 vs. 13.0 months for pelvic and UA vs. EP only recurrences (p=0.02). Similarly, median OS was 29.2 months for pelvic and UA and not reached for EP only (p=0.05). For interval CRS+HIPEC, there was no difference in median PFS (10.6 vs. 11.7 months, p=0.68) and OS (27.1 vs. 24.8 months, p=0.96) for pelvic and UA vs EP alone. However, for recurrent CRS+HIPEC, pelvic and UA sites of recurrence were associated with reduced PFS (10.0 vs. 18.1 months, p=0.03) and OS (33.6 months vs. not reached, p=0.02) vs. EP only. CONCLUSIONS: In women with advanced or recurrent EOC undergoing CRS+HIPEC, one-half of patients experience their first recurrence outside of the peritoneal cavity. Providers must be aware of the risk of EP failure in patients treated with CRS+HIPEC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chambers LM, Yao M, Morton M, et al. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecol Oncol. 2021. PMID: 33551202. doi:10.1016/j.ygyno.2021.01.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。